BioVaxys Technology Corp.

BioVaxys Technology Corp. is a clinical-stage biotechnology company that aims to enhance patient lives through innovative immunotherapies. The company leverages its DPX™ immune-educating delivery technology platform and HapTenix© neoantigen tumor cell construct platform to develop treatments for cancers, infectious diseases, antigen desensitization, and other immunological fields. Their clinical stage pipeline includes maveropepimut-S, currently in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, as well as BVX-0918, a personalized immunotherapeutic vaccine utilizing the HapTenix© platform, soon to enter Phase I in Spain for refractive late-stage ovarian cancer treatment.

BioVaxys capitalizes on its tumor immunology expertise and the creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines. This enables them to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

Founded in 2020, BioVaxys operates in the Biopharma and Biotechnology industries. While the specific headquarters location and recent investment details are unavailable, the company's dedication to pioneering immunotherapies positions them as a compelling prospect for venture capital consideration.